Combretastatin-induced hypertension and the consequences for its combination with other therapies

Vascular Pharmacology

Volumn 54, Issue 1-2, 2011, Pages 13-17

  Busk, Morten ^a   Bohn, Anja Bille ^a   Skals, Marianne ^b   Wang, Tobias ^b   Horsman, Michael R ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Combretastatin; Elevated hematocrit; Hydralazine; Hypertension; Multimodality treatment

Indexed keywords

COMBRETASTATIN A4 PHOSPHATE; HEMOGLOBIN; HYDRALAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE MONITORING; BREAST CARCINOMA; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HYPERTENSION; HYPERTHERMIA; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOOD PRESSURE; COMBINED MODALITY THERAPY; FEMALE; HEMATOCRIT; HEMOGLOBINS; HYDRALAZINE; HYPERTENSION; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOVASCULARIZATION, PATHOLOGIC; STILBENES;

EID: 79952621559     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2010.10.002     Document Type: Article

References (29)

1. Ahmed F., Steele J.C., Herbert J.M., Steven N.M., Bicknell R. Tumor stroma as a target in cancer. Curr. Cancer Drug Targets 2008, 8:447-453.
2. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
3. Chaplin D.J., Pettit G.R., Hill S.A. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res. 1999, 19:189-195.
4. Christensen K.L., Horsman M.R., Overgaard J. Invasive blood pressure measurements in restrained but non-anaesthetized mice. In Vivo 1990, 4:13-16.
5. Diwan A., Koesters A.G., Odley A.M., Pushkaran S., Baines C.P., Spike B.T., Daria D., Jegga A.G., Geiger H., Aronow B.J., Molkentin J.D., Macleod K.F., Kalfa T.A., Dorn G.W. Unrestrained erythroblast development in Nix-/- mice reveals a mechanism for apoptotic modulation of erythropoiesis. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:6794-6799.
6. Fisker R.V., Horsman M.R., Overgaard J. Hydralazine-induced changes in tissue perfusion and radiation response in a C3H mammary carcinoma and mouse normal tissues. Acta Oncol. 1991, 30:641-647.
7. Horsman M.R., Siemann D.W. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res. 2006, 66:11520-11539.
8. Horsman M.R., Christensen K.L., Overgaard J. Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo. Int. J. Hyperthermia 1989, 5:123-136.
9. Horsman M.R., Christensen K.L., Overgaard J. Relationship between the hydralazine-induced changes in murine tumor blood supply and mouse blood pressure. Int. J. Radiat. Oncol. Biol. Phys. 1992, 22:455-458.
10. Hurford W.E., Hochachka P.W., Schneider R.C., Guyton G.P., Stanek K.S., Zapol D.G., Liggins G.C., Zapol W.M. Splenic contraction, catecholamine release, and blood volume redistribution during diving in the Weddell seal. J. Appl. Physiol. 1996, 80:298-306.
11. Ke Q., Bodyak N., Rigor D.L., Hurst N.W., Chaplin D.J., Kang P.M. Pharmacological inhibition of the hypertensive response to combretastatin A-4 phosphate in rats. Vascul. Pharmacol. 2009, 51:337-343.
12. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2002, 2:727-739.
13. Murata R., Overgaard J., Horsman M.R. Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2001, 51:1018-1024.
14. Murata R., Siemann D.W., Overgaard J., Horsman M.R. Improved tumor response by combining radiation and the vascular-damaging drug 5, 6-dimethylxanthenone-4-acetic acid. Radiat. Res. 2001, 156:503-509.
15. Murata R., Siemann D.W., Overgaard J., Horsman M.R. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother. Oncol. 2001, 60:155-161.
16. Nielsen T., Murata R., Maxwell R.J., Stodkilde-Jorgensen H., Ostergaard L., Horsman M.R. Preclinical studies to predict efficacy of vascular changes induced by combretastatin A-4 disodium phosphate in patients. Int. J. Radiat. Oncol. Biol. Phys. 2008, 70:859-866.
17. Overgaard J. Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo. Int. J. Radiat. Oncol. Biol. Phys. 1980, 6:1507-1517.
18. Persson S.G., Ekman L., Lydin G., Tufvesson G. Circulatory effects of splenectomy in the horse. I. Effect on red-cell distribution and variability of haematocrit in the peripheral blood. Zentralbl. Veterinarmed. A. 1973, 20:441-455.
19. Persson S.G., Ekman L., Lydin G., Tufvesson G. Circulatory effects of splenectomy in the horse. II. Effect on plasma volume and total and circulating red-cell volume. Zentralbl. Veterinarmed. A. 1973, 20:456-468.
20. Prise V.E., Honess D.J., Stratford M.R., Wilson J., Tozer G.M. The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int. J. Oncol. 2002, 21:717-726.
21. Richardson M.X., de Bruijn R., Schagatay E. Hypoxia augments apnea-induced increase in hemoglobin concentration and hematocrit. Eur. J. Appl. Physiol. 2009, 105:63-68.
22. Rustin G.J., Galbraith S.M., Anderson H., Stratford M., Folkes L.K., Sena L., Gumbrell L., Price P.M. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J. Clin. Oncol. 2003, 21:2815-2822.
23. Siemann D.W., Horsman M.R. Vascular targeted therapies in oncology. Cell Tissue Res. 2009, 335:241-248.
24. Siemann D.W., Rojiani A.M. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int. J. Radiat. Oncol. Biol. Phys. 2002, 53:164-171.
25. Siemann D.W., Chaplin D.J., Horsman M.R. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004, 100:2491-2499.
26. Siemann D.W., Bibby M.C., Dark G.G., Dicker A.P., Eskens F.A., Horsman M.R., Marme D., Lorusso P.M. Differentiation and definition of vascular-targeted therapies. Clin. Cancer Res. 2005, 11:416-420.
27. Siemann D.W., Chaplin D.J., Walicke P.A. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin. Investig. Drugs 2009, 18:189-197.
28. Tozer G.M., Prise V.E., Wilson J., Locke R.J., Vojnovic B., Stratford M.R., Dennis M.F., Chaplin D.J. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. 1999, 59:1626-1634.
29. Tozer G.M., Prise V.E., Wilson J., Cemazar M., Shan S., Dewhirst M.W., Barber P.R., Vojnovic B., Chaplin D.J. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res. 2001, 61:6413-6422.